stockrowPerspective Therapeutics, Inc. (CATX) vs MaxCyte, Inc. (MXCT)
- Perspective Therapeutics, Inc. CATX 0.84 +6.33%
- MaxCyte, Inc. MXCT 1.30 −0.76%
Perspective Therapeutics, Inc. and MaxCyte, Inc. are both Medical Devices companies. MaxCyte, Inc. is the larger, with a market value of $135.2M against $90.0M — 1.5× the size. MaxCyte, Inc. grew revenue faster over the last twelve months: −13.2% against −66.9%. MaxCyte, Inc. has the higher net margin (−114.8% vs −28,468.0%) and the higher return on invested capital (−49.2% vs −88.4%). Across the 18 metrics below, MaxCyte, Inc. leads on 14 and Perspective Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | CATX | MXCT | Medical Devices median |
|---|---|---|---|
| Gross margin | 100.00% | 79.23% | 57.76% |
| Operating margin | (30,619.07%) | (134.59%) | (15.07%) |
| Net margin | (28,467.97%) | (114.77%) | (14.45%) |
| Free cash flow margin | (29,630.07%) | (76.14%) | (3.88%) |
| Return on equity | (39.50%) | (20.39%) | (10.35%) |
| Return on assets | (33.14%) | (17.62%) | (17.26%) |
| Return on invested capital | (88.41%) | (49.23%) | (5.27%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack